Pay in 4 interest-free payments of $6.48 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
Therefore, whether patients on anticoagulant therapy should undergo this procedure is unclear
To minimize selection bias, we employed 1:1 propensity score matching to account for demographic factors such as age, sex, race, and comorbidities
Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
Hypotensive symptoms (dizziness, blurred vision, weakness) warrant immediate provider contact
Clinicians are described as working through the platform, but not as MEDVi employees
The NDA was based on results from the OASIS-4 trial in adults with obesity or overweight
US$ 26.88
US$ 21.72
US$ 26.56
US$ 29.30
US$ 21.24
